[go: up one dir, main page]

MX2020004644A - Nano-particulas que contienen variantes sinteticas del gangliosido gm3 como adyuvantes en vacunas. - Google Patents

Nano-particulas que contienen variantes sinteticas del gangliosido gm3 como adyuvantes en vacunas.

Info

Publication number
MX2020004644A
MX2020004644A MX2020004644A MX2020004644A MX2020004644A MX 2020004644 A MX2020004644 A MX 2020004644A MX 2020004644 A MX2020004644 A MX 2020004644A MX 2020004644 A MX2020004644 A MX 2020004644A MX 2020004644 A MX2020004644 A MX 2020004644A
Authority
MX
Mexico
Prior art keywords
ganglioside
vaccines
adjuvants
nano
particles
Prior art date
Application number
MX2020004644A
Other languages
English (en)
Inventor
Ramírez Belinda Sánchez
Suárez Narjara González
Molina Luis Enrique Fernández
Gómez Audry Fernández
Báez Gretchen Bergado
Pardillo Circe Mesa
García Lisset Chao
Martínez Dayana Pérez
Fernández Diana Rosa Hernández
Rodríguez Mabel Cruz
Vargas Ángel Alexis Manso
Bencomo Vicente Guillermo Verez
Murguía Blanca Idelmis Tolón
López Miguel Antonio López
BARRANCO Jesús Arturo JUNCO
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of MX2020004644A publication Critical patent/MX2020004644A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención describe la forma de obtener adyuvantes nano-particulados basados en diferentes variantes sintéticas del gangliosido GM3; en dependencia de la estructura fina del acido graso presente en el ceramido del GM3 sintético, se pueden obtener adyuvantes que sirven para estimular específica y especializadamente la respuesta inmune humoral o la celular contra antígenos acompañantes; particularmente, esta invención provee composiciones vacunales inmunogenicas que comprenden péptidos, polipéptidos o proteínas y las antes mencionadas nano-partículas, que se forman mediante la dispersión de proteínas hidrofóbicas del complejo de membrana externa (CPME) de la bacteria Neisseria meningitidis con variantes totalmente sintéticas del gangliosido GM3.
MX2020004644A 2017-11-06 2018-10-24 Nano-particulas que contienen variantes sinteticas del gangliosido gm3 como adyuvantes en vacunas. MX2020004644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2017000137A CU24534B1 (es) 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
PCT/CU2018/050003 WO2019086056A1 (es) 2017-11-06 2018-10-24 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas

Publications (1)

Publication Number Publication Date
MX2020004644A true MX2020004644A (es) 2020-07-24

Family

ID=64745822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004644A MX2020004644A (es) 2017-11-06 2018-10-24 Nano-particulas que contienen variantes sinteticas del gangliosido gm3 como adyuvantes en vacunas.

Country Status (18)

Country Link
US (2) US11806396B2 (es)
EP (1) EP3711775A1 (es)
JP (1) JP7332592B2 (es)
KR (1) KR102728174B1 (es)
CN (1) CN111295200B (es)
AR (1) AR114139A1 (es)
AU (1) AU2018359358B2 (es)
BR (1) BR112020008668A2 (es)
CA (1) CA3079105A1 (es)
CO (1) CO2020006548A2 (es)
CU (1) CU24534B1 (es)
EA (1) EA202091116A1 (es)
MX (1) MX2020004644A (es)
MY (1) MY204283A (es)
SG (1) SG11202004180SA (es)
TW (1) TWI719351B (es)
WO (1) WO2019086056A1 (es)
ZA (1) ZA202003218B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU24637B1 (es) 2019-12-24 2022-12-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen
CU24705B1 (es) 2020-10-22 2024-06-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1
CN121130071A (zh) * 2025-11-17 2025-12-16 重庆市畜牧科学院 一种含有免疫佐剂的多肽纳米颗粒疫苗及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
US7776346B2 (en) 2003-05-22 2010-08-17 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal product compositions comprising structured benefit agent premix or delivery vehicle
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
CU23739A1 (es) * 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Also Published As

Publication number Publication date
JP2021501792A (ja) 2021-01-21
TW201927804A (zh) 2019-07-16
ZA202003218B (en) 2022-05-25
NZ764565A (en) 2024-02-23
CO2020006548A2 (es) 2020-08-21
BR112020008668A2 (pt) 2020-10-06
TWI719351B (zh) 2021-02-21
EP3711775A1 (en) 2020-09-23
KR102728174B1 (ko) 2024-11-11
AU2018359358A1 (en) 2020-06-11
CU24534B1 (es) 2021-07-02
SG11202004180SA (en) 2020-06-29
US11806396B2 (en) 2023-11-07
US20200268878A1 (en) 2020-08-27
CN111295200A (zh) 2020-06-16
CN111295200B (zh) 2025-05-16
US12280109B2 (en) 2025-04-22
EA202091116A1 (ru) 2020-09-24
CU20170137A7 (es) 2019-06-04
MY204283A (en) 2024-08-21
JP7332592B2 (ja) 2023-08-23
AU2018359358B2 (en) 2022-08-04
KR20200086315A (ko) 2020-07-16
WO2019086056A1 (es) 2019-05-09
AR114139A1 (es) 2020-07-29
CA3079105A1 (en) 2019-05-09
US20240131152A1 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
PH12018500985A1 (en) Proflavour delivery particles
PH12017500762A1 (en) Proflavor delivery particles
MY202415A (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2020003760A (es) Formulaciones de niraparib.
SG11201700862VA (en) Synchronizing breast pumping with infant feeding
MX2020004424A (es) Formulacion aerosolizable.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020004205A (es) Composiciones antibioticas de ceftolozano.
IN2015DE00625A (es)
MY165760A (en) Absorbent article
ZA202003218B (en) Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
MX2020003617A (es) Dispositivo de preparacion de cables.
IL252972A0 (en) Antigen delivery system
MX2020003440A (es) Red de seguridad.
MY167350A (en) Fat-and-oil composition and chocolate
MX2020003703A (es) Composiciones de sabor.
MX2017005961A (es) Polvos para suministro de precursores.
MX2020004664A (es) Dispositivo generador de humo mejorado.
AU364465S (en) Bottle
AU201616281S (en) Bottle
AU201711477S (en) Bottle
AU201711478S (en) Bottle
AU201711349S (en) Bottle
AU201613375S (en) Bottle